WeinzimerSA, DziuraJ, SteilGM, KurtzN, SwanKL, TamborlaneWV. Fully closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care, 2008; 31:934–939.
4.
KraegenEW, ChisholmDJ, McNamaraME. Timing of insulin delivery with meals. Horm Metab Res, 1981; 13:365–367.
5.
ChisholmDJ, KraegenEW, BellDJ, ChippsDR. A semi-closed loop computer-assisted insulin infusion system. Hospital use for control of diabetes in patients. Med J Aust, 1984; 22:784–789.
6.
KraegenEW. Closed-loop systems: physiological and practical considerations. BrunettiP, AlbertiKGMM, AlbisserAM, HeppKD, Massi BenedettiM. Artificial Systems for Insulin Delivery. New York: Raven Press, 1983; 457–464.
7.
PickupJC, VibertiGC, BilousRW, KeenH, AlbertiKGMM, HomePD, BinderC. Safety of continuous subcutaneous insulin infusion. Metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia, 1982; 22:175–179.
8.
AttiaN, JonesTW, HolcombeJ, TamborlaneWV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care, 1998; 21:817–821.
9.
GuerciB, MeyerL, SalléA, CharriéA, DoussetB, ZieglerO, DrouinP. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab, 1999; 84:2673–2678.
10.
KrzentowskiG, SheenA, CastilloM, LuyckxAS, LefebvrePJ. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia, 1983; 24:314–318.
11.
ElleriD, AllenJM, NodaleM, WilinskaME, AceriniCL, DungerDB, HovorkaR. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diabet Med, 2010; 27:480–484.
12.
CengizE, SwanKL, TamborlaneWV, SteilGM, SteffanAT, WeinzimerS. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther, 2009; 11:207–210.
13.
ChoudharyP, ShinJ, WangY, EvansML, HammondPJ, KerrD, ShawJA, PickupJC, AmielSA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care(in press).
14.
DanneT, KordonouriO, RemusK, HolderM, WadienT, HaberlandH, GolembowskiS, ZierowS, ThomasA. Prevention of hypoglycaemia by using low glucose suspend (LGS) function in sensor-augmented pump therapy [abstract]Diabetes Technol Ther, 2011; 13:217.
